Rituxan for Chronic GVHD
Dear OncoLink "Ask The Experts,"
My brother has chronic GVHD and all other treatments have failed so far. His doctor now has decided to try Rituximab. What can you tell me about this?
Deana Potts, MSN, CRNP, Advanced Practice Oncology Nurse, responds:
B-cells and T-cells are part of the immune system. GVHD, or graft versus host disease, is caused by donor T-cells that see the recipient as foreign and thus attack the recipient. Rituximab is a medication that is actually directed against B-cells. It is believed that you need B cells in order to activate T cells. So by removing the B cells with Rituximab, the T cells become less functional and therefore may mount less of a graft versus host response.
Rituximab is being used in limited cases, and should be considered somewhat "investigational" in this setting. Although it is safe, the response rate is largely unknown. It is a reasonable alternative when traditional therapies are not working.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania